Astellas Pharma Inc (4503.T) stock: key figures, P/E, revenue and dividend

Health Care · Japan · ISIN JP3942400007

Price
2,496.00 JPY
Market cap
4.48 tn JPY
P/E (2026)
15.38
P/S (2026)
2.10
Dividend yield
3.17 %
Net margin
13.63 %
Return on equity (ROE)
15.94 %
Return on assets (ROA)
8.17 %

Astellas Pharma Inc financials

Fiscal year20252026
Revenue1.91 tn JPY2.14 tn JPY
Gross profit1.56 tn JPY1.59 tn JPY
EBIT263.54 bn JPY419.70 bn JPY
Net income50.75 bn JPY291.54 bn JPY
Diluted EPS – continuing operations28.23 JPY162.31 JPY

Full history since 1994, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Astellas Pharma Inc

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.